During the past decade, Azienda Sanitaria Universitaria Integrata Di Trieste conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 4 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 4 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Sanitaria Universitaria Integrata Di Trieste" #1 sponsor was "Boehringer Ingelheim" with 3 trials, followed by "Kowa Research Europe" with 3 trials sponsored, "Azienda Ospedaliera Universitaria Integrata Verona" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Catholic University of the Sacred Heart" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Sanitaria Universitaria Integrata Di Trieste" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Agenzia Italiana del Farmaco" with 2 trials as a collaborator, "Azienda Sanitaria-Universitaria Integrata di Udine" with 2 trials as a collaborator, "Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Sanitaria Universitaria Integrata Di Trieste" are "Dyslipidemia" (3 trials), "Heart Failure" (3 trials), "COVID-19" (2 trials), "Hypercholesterolemia" (2 trials) and "Atelectasis, Postoperative Pulmonary" (1 trials). Many other conditions were trialed in "Azienda Sanitaria Universitaria Integrata Di Trieste" in a lesser frequency.

Most popular intervention types in "Azienda Sanitaria Universitaria Integrata Di Trieste" are "Drug" (13 trials), "Other" (2 trials), "Biological" (1 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Empagliflozin" (3 trials), "Pitavastatin" (3 trials), "Rituximab" (2 trials) and "Sotrovimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Sanitaria Universitaria Integrata Di Trieste" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Azienda Sanitaria Universitaria Integrata Di Trieste". undefined are not yet recruiting, 6 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Azienda Sanitaria Universitaria Integrata Di Trieste, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Sanitaria Universitaria Integrata Di Trieste, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".